Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16565532 | 0.85 | P2RX7 (0.67) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL28077553 | 0.84 | DRD2 (0.50) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL21078014 | 0.84 | DRD3 (0.56) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL16554105 | 0.82 | DRD2 (0.50) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL21214320 | 0.82 | DRD3 (0.54) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL20004044 | 0.81 | P2RX7 (0.43) | DRD2DRD3DRD4P2RX7MCHR1 | |
| SCHEMBL16553797 | 0.80 | EPHX2 (0.41) | DRD2DRD3DRD4P2RX7SLC6A2 | |
| SCHEMBL17886638 | 0.79 | DRD2 (0.46) | DRD2DRD3DRD4P2RX7SLC6A2 | |
| SCHEMBL20004195 | 0.79 | OPRM1 (0.41) | DRD2P2RX7SLC6A4SLC6A3KCNH2 | |
| SCHEMBL16553711 | 0.79 | DRD2 (0.53) | DRD2DRD3DRD4P2RX7MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086757-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | DRD2 1347/4885DRD3 1418/4885DRD4 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.